Drug Approval | February 24, 2026
FDA approves Lilly's Zepbound multi-dose KwikPen for obesity treatment
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
BREAKWATER is a Phase 3, randomized, open-label trial testing BRAFTOVI in combination with cetuximab, either alone or with chemotherapy, in patients with untreated BRAF V600E-mutant mCRC
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
PreemieFort Enteral Solution's approval marks the first time a nutritional product derived from human milk has been recognized as a prescription medicine anywhere in the world
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
Subscribe To Our Newsletter & Stay Updated
